User: Guest  Login
Title:

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Document type:
Article; Journal Article
Author(s):
Eckstein, Markus; Erben, Philipp; Kriegmair, Maximilian C; Worst, Thomas S; Weis, Cleo-Aron; Wirtz, Ralph M; Wach, Sven; Stoehr, Robert; Sikic, Danijel; Geppert, Carol I; Weyerer, Veronika; Bertz, Simone; Breyer, Johannes; Otto, Wolfgang; Keck, Bastian; Burger, Maximilian; Taubert, Helge; Weichert, Wilko; Wullich, Bernd; Bolenz, Christian; Hartmann, Arndt; Erlmeier, Franziska
Abstract:
BACKGROUND: Recently, the Food and Drug Administration (FDA)/European Medicines Agency (EMA) restricted first-line use of atezolizumab and pembrolizumab in patients with metastasised urothelial carcinoma by defining distinct programmed cell death ligand-1 cut-offs. We analysed the diagnostic performance of all FDA/EMA-approved programmed cell death ligand-1 assays with emphasis on new restrictions for first-line treatment with atezolizumab and pembrolizumab. PATIENTS AND METHODS: Two hundred fif...     »
Journal title abbreviation:
Eur J Cancer
Year:
2019
Journal volume:
106
Pages contribution:
234-243
Language:
eng
Fulltext / DOI:
doi:10.1016/j.ejca.2018.11.007
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/30528808
Print-ISSN:
0959-8049
TUM Institution:
Institut für Allgemeine Pathologie und Pathologische Anatomie
 BibTeX